1
|
Roth M, King L, St Cyr K, Mohsin U, Balderson K, Rhind S, Goldman A, Richardson D. Evaluating the prospective utility of pharmacogenetics reporting among Canadian Armed Forces personnel receiving pharmacotherapy: a preliminary assessment towards precision psychiatric care. BMJ Mil Health 2023:e002447. [PMID: 37657847 DOI: 10.1136/military-2023-002447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 07/18/2023] [Indexed: 09/03/2023]
Abstract
Pharmacological interventions for treating posttraumatic stress disorder in Canadian Armed Forces (CAF) members and Veterans often achieve modest results. The field of pharmacogenetics, or the study of how genes influence an individual's response to different medications, offers insight into how prior knowledge of gene-drug interactions may potentially improve the trial-and-error process of drug selection in pharmacotherapy, thereby improving treatment effects and remission rates. Given the relative recency of pharmacogenetics testing and sparse research in military samples, we used pharmacogenetics testing in a small pilot group (n=23) of CAF members and Veterans who were already engaged in pharmacotherapy for a service-related mental health condition to better understand the associated opportunities and challenges of pharmacogenetics testing in this population. Our preliminary evaluation involved: (1) reporting the prevalence of pharmacogenetics testing 'bin' status according to participants' reports ('green', 'yellow' or 'red'; intending to signal 'go', 'caution' or 'stop', regarding the potential for gene-drug interactions); (2) calculating the percentage of currently prescribed psychotropic medications that were assessed and included in the reports; (3) evaluating whether prescribers used pharmacogenetics testing information according to clinical notes and (4) collecting informal feedback from participating psychiatrists. While pharmacogenetics testing appeared to provide valuable information for a number of clients, a major limitation was the number of commonly prescribed medications not included in the reports.
Collapse
Affiliation(s)
- Maya Roth
- Operational Stress Injury Clinic-Greater Toronto Site, St. Joseph's Health Care, London, Toronto, Ontario, Canada
- MacDonald Franklin Operational Stress Injury Research Centre, London, Ontario, Canada
| | - L King
- Operational Stress Injury Clinic - Parkwood Main Site, SJHC, London, Ontario, Canada
| | - K St Cyr
- MacDonald Franklin Operational Stress Injury Research Centre, London, Ontario, Canada
- University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada
| | - U Mohsin
- University of Toronto, Toronto, Ontario, Canada
| | - K Balderson
- Operational Stress Injury Clinic - Parkwood Main Site, SJHC, London, Ontario, Canada
| | - S Rhind
- Defence Research and Development Canada, Toronto, Ontario, Canada
| | - A Goldman
- DNA Labs Canada Inc, Toronto, Ontario, Canada
| | - D Richardson
- MacDonald Franklin Operational Stress Injury Research Centre, London, Ontario, Canada
- Operational Stress Injury Clinic - Parkwood Main Site, SJHC, London, Ontario, Canada
| |
Collapse
|
2
|
de Los Ángeles Aldirico M, Giorgio FM, Soto A, Sibilia MDP, Sánchez VR, Picchio MS, Rattay G, Arcon N, Moretta R, Martín V, Goldman A, Fenoy IM. Maternal stress increases risk of allergic lung inflammation in adult mice. Immunobiology 2023; 228:152395. [PMID: 37210753 DOI: 10.1016/j.imbio.2023.152395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 05/08/2023] [Accepted: 05/14/2023] [Indexed: 05/23/2023]
Abstract
BACKGROUND Allergies are increasing worldwide. The presence of atopic diseases in the mother propagates the onset of allergic diseases in the offspring with a considerably stronger penetrance than atopic diseases of the father. Such observation challenges genetic predispositions as the sole cause of allergic diseases. Epidemiological studies suggest that caregiver stress in the perinatal period may predispose offspring to asthma. Only one group has studied the link between prenatal stress and neonatal asthma susceptibility in a murine model. OBJECTIVES We aimed to study if the neonatal increased risk of developing allergic lung inflammation persists after puberty and if there are sex differences in susceptibility. METHODS Pregnant BALB/c mice were subjected to a single restraint stress exposure at day 15 of gestation. Pups were separated by gender and subjected to a well-known sub-optimal asthma model after puberty. RESULTS Adult mice born to stressed dams were more susceptible to developing allergic pulmonary inflammation since an increase in the number of eosinophils in bronchoalveolar lavage (BAL), a greater peribronchial and perivascular infiltrate, a higher proportion of mucus-producing cells, and increased IL-4 and IL-5 levels in BAL were detected compared to control mice. These effects were more profound in females than males. Moreover, only females from stressed dams showed an increase in IgE levels. CONCLUSIONS Increased litter susceptibility to develop allergic lung inflammation induced by maternal stress persists after puberty and is more potent in females than in male mice.
Collapse
Affiliation(s)
| | | | - Ariadna Soto
- ITECA, ECyT UNSAM, CONICET, Gral. San Martín, Buenos Aires, Argentina
| | | | | | | | - Guido Rattay
- ITECA, ECyT UNSAM, CONICET, Gral. San Martín, Buenos Aires, Argentina
| | - Nadia Arcon
- ITECA, ECyT UNSAM, CONICET, Gral. San Martín, Buenos Aires, Argentina
| | - Rosalía Moretta
- ITECA, ECyT UNSAM, CONICET, Gral. San Martín, Buenos Aires, Argentina
| | - Valentina Martín
- ITECA, ECyT UNSAM, CONICET, Gral. San Martín, Buenos Aires, Argentina
| | - Alejandra Goldman
- ITECA, ECyT UNSAM, CONICET, Gral. San Martín, Buenos Aires, Argentina
| | | |
Collapse
|
3
|
Galffy G, Lugowska I, Poddubskaya EV, Cho BC, Ahn MJ, Han JY, Su WC, Hauke RJ, Dyar SH, Lee DH, Serwatowski P, Estelles DL, Holden VR, Kim YJ, Vladimirov V, Horvath Z, Ghose A, Goldman A, di Pietro A, Wang J, Murphy DA, Alhadab A, Laskov M. A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer. ESMO Open 2023; 8:101173. [PMID: 37141847 DOI: 10.1016/j.esmoop.2023.101173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 01/17/2023] [Accepted: 02/06/2023] [Indexed: 05/06/2023] Open
Abstract
BACKGROUND We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). PATIENTS AND METHODS We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. RESULTS A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (≥median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (<median) in the NSCLC cohort and higher TMB (≥median) in the UC cohort. Treatment-related adverse events (TRAEs) occurred in 93.4% of patients, including grade ≥3 TRAEs in 55.7%. Avelumab exposures with 800 mg Q2W dosing were similar to those observed with 10 mg/kg Q2W dosing. CONCLUSIONS In previously treated patients with advanced/metastatic NSCLC, ORR appeared to be superior to anti-PD-L1 or anti-programmed cell death protein 1 monotherapy, irrespective of PD-L1 status, whereas in untreated, cisplatin-ineligible patients with advanced/metastatic UC, ORR was lower than expected, potentially limited by small patient numbers. TRIAL REGISTRATION Clinicaltrial.gov NCT03472560; https://clinicaltrials.gov/ct2/show/NCT03472560.
Collapse
Affiliation(s)
- G Galffy
- Department of Pulmonology, Pulmonology Hospital Törökbálint, Törökbálint, Hungary.
| | - I Lugowska
- Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
| | | | - B C Cho
- Division of Medical Oncology, Yonsei Cancer Center, Severance Hospital, Seoul
| | - M-J Ahn
- Department of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J-Y Han
- Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea
| | - W-C Su
- Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
| | - R J Hauke
- Department of Oncology, Nebraska Cancer Specialists, Omaha
| | - S H Dyar
- Department of Hematology & Oncology, Saint Francis Hospital Cancer Center, Greenville, USA
| | - D H Lee
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | | | - D L Estelles
- Department of Oncology, Consorcio Hospitalario Provincial de Castellon, Castellon, Spain
| | - V R Holden
- Oncology Hematology Associates, Springfield, USA
| | - Y J Kim
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea
| | - V Vladimirov
- GBUZ of Stavropol Territory Pyatigorsk Inter-regional Oncology Dispensary, Pyatigorsk, Stavropol Territory, Russia
| | - Z Horvath
- Bács-Kiskun Megyei Kórház Onkoradiológiai Központ, Kecskemet, Hungary
| | - A Ghose
- Department of Medical Oncology/Hematology, Arizona Oncology Associates, Tempe
| | | | | | | | | | | | - M Laskov
- LLC University Clinic of Headache, Moscow, Russia
| |
Collapse
|
4
|
Schoelmerich MO, Döppner T, Allen CH, Divol L, Oliver M, Haden D, Biener M, Crippen J, Delora-Ellefson J, Ferguson B, Gericke DO, Goldman A, Haid A, Heinbockel C, Kalantar D, Karmiol Z, Kemp G, Kroll J, Landen OL, Masters N, Ping Y, Spindloe C, Theobald W, White TG. Developing a platform for Fresnel diffractive radiography with 1 μm spatial resolution at the National Ignition Facility. Rev Sci Instrum 2023; 94:013104. [PMID: 36725556 DOI: 10.1063/5.0101890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 01/04/2023] [Indexed: 06/18/2023]
Abstract
An x-ray Fresnel diffractive radiography platform was designed for use at the National Ignition Facility. It will enable measurements of micron-scale changes in the density gradients across an interface between isochorically heated warm dense matter materials, the evolution of which is driven primarily through thermal conductivity and mutual diffusion. We use 4.75 keV Ti K-shell x-ray emission to heat a 1000 μm diameter plastic cylinder, with a central 30 μm diameter channel filled with liquid D2, up to 8 eV. This leads to a cylindrical implosion of the liquid D2 column, compressing it to ∼2.3 g/cm3. After pressure equilibration, the location of the D2/plastic interface remains steady for several nanoseconds, which enables us to track density gradient changes across the material interface with high precision. For radiography, we use Cu He-α x rays at 8.3 keV. Using a slit aperture of only 1 μm width increases the spatial coherence of the source, giving rise to significant diffraction features in the radiography signal, in addition to the refraction enhancement, which further increases its sensitivity to density scale length changes at the D2/plastic interface.
Collapse
Affiliation(s)
- M O Schoelmerich
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - T Döppner
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - C H Allen
- Department of Physics, University of Nevada, Reno, 1664 N Virginia St., Reno, Nevada 89557, USA
| | - L Divol
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - M Oliver
- Central Laser Facility, STFC Rutherford-Appleton Laboratory, Chilton OX11 0QX, United Kingdom
| | - D Haden
- Department of Physics, University of Nevada, Reno, 1664 N Virginia St., Reno, Nevada 89557, USA
| | - M Biener
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - J Crippen
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - J Delora-Ellefson
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - B Ferguson
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - D O Gericke
- Centre for Fusion, Space and Astrophysics, Department of Physics, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - A Goldman
- Department of Physics, University of Nevada, Reno, 1664 N Virginia St., Reno, Nevada 89557, USA
| | - A Haid
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - C Heinbockel
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - D Kalantar
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - Z Karmiol
- Department of Physics, University of Nevada, Reno, 1664 N Virginia St., Reno, Nevada 89557, USA
| | - G Kemp
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - J Kroll
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - N Masters
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - Y Ping
- Lawrence Livermore National Laboratory, L-493, 7000 East Avenue, Livermore, California 94550, USA
| | - C Spindloe
- Central Laser Facility, STFC Rutherford-Appleton Laboratory, Chilton OX11 0QX, United Kingdom
| | - W Theobald
- Laboratory for Laser Energetics, 250 E River Rd., Rochester, New York 14623, USA
| | - T G White
- Department of Physics, University of Nevada, Reno, 1664 N Virginia St., Reno, Nevada 89557, USA
| |
Collapse
|
5
|
Wollina U, Goldman A. UPPER ARM CONTOURING - A NARRATIVE REVIEW. Georgian Med News 2022:29-35. [PMID: 36701774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Disfigurement of upper arms is a common esthetic problem. All soft tissues contribute with skin and subcutaneous adipose tissue as the major targets of medical intervention. This narrative review describes the complex pathogenesis of upper arm ptosis and its classification. Surgical and non-surgical methods to improve upper arm contour are discussed. With the broad spectrum of available treatments, a tailored approach is possible to address the individual patient's needs.
Collapse
Affiliation(s)
- U Wollina
- 1Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
| | - A Goldman
- 2Department of Plastic Surgery, Hospital São Lucas da PUCRS, Porto Alegre, Brazil
| |
Collapse
|
6
|
Goldman A, Fishman B, Raschi E, Cukierman-Yaffe T, Dankner R, Ben-Zvi I, Maor E. The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
As indications for sodium-glucose co-transporter-2 (SGLT2) inhibitors treatment are expanding, more older adults become candidates for treatment. However, data regarding the treatment's safety profile in the older population are limited.
Methods
A retrospective, pharmacovigilance study of the FDA's global database of safety reports (7/1/2014–6/30/2021). To assess reporting of pre-specified adverse events following SGLT2-inhibitors treatment among adults (18≥age<75) and older adults (age≥75), we performed disproportionality analysis using the reporting odds ratio (ROR).
Results
Of 10,526,408 patients in the full database, 279,619 eligible patients with non-insulin-dependent diabetes mellitus were identified (mean age 63.4 [SD 13.0] years, 54,791 [19.6%] aged ≥75 years), among whom 29,431 receiving SGLT-2 inhibitors. Compared to other non-insulin anti-diabetics, SGLT2-inhibitors were significantly associated with amputations (ROR=127.87 [95% CI: 111.31–146.90] vs ROR=74.91 [49.99–112.25]), Fournier gangrene (ROR=53.27 [44.38–63.92] vs ROR=33.33 [20.33–54.64]), diabetes ketoacidosis (ROR=39.25 [37.20–41.42] vs ROR=58.46 [49.41–69.1]), genitourinary infections (ROR=4.36 [4.12–4.61] vs ROR=5.08 [4.45–5.79]), nocturia (ROR=2.81 [2.13–3.73] vs ROR=3.51 [1.84–6.68]), and dehydration (ROR=2.22 [2.05–2.40] vs ROR=2.33 [1.93–2.81]) in both adults and older adults, respectively. The relative reporting of these safety signals was consistent between age groups (all P interaction >0.05). Acute kidney injury was associated with SGLT2-inhibitors treatment in adults (ROR=1.47 [1.40–1.54]) but not older adults (ROR=0.84 [0.72–0.98]). No new safety signals were observed in older adults. Falls, fractures, hypotension, and syncope were not associated with SGLT2-inhibitors among either adults or older adults.
Conclusion
In this global post-marketing study, treatment with SGLT-2 inhibitors in older adults was associated with increased reporting of amputations, Fournier gangrene, DKA, genitourinary infections, and dehydration. Nevertheless, the relative reporting was consistent between adults and older adults, and no new safety signals were found in the older population.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Goldman
- The Chaim Sheba Medical Center , Tel Hashomer , Israel
| | - B Fishman
- The Chaim Sheba Medical Center , Tel Hashomer , Israel
| | - E Raschi
- Alma Mater Studiorum, University of Bologna, Pharmacology Unit, Department of Medical and Surgical Sciences , Bologna , Italy
| | | | - R Dankner
- Gertner Institute for Epidemiology and Health Policy Research , Ramat Gan , Israel
| | - I Ben-Zvi
- The Chaim Sheba Medical Center , Tel Hashomer , Israel
| | - E Maor
- The Chaim Sheba Medical Center , Tel Hashomer , Israel
| |
Collapse
|
7
|
Soto A, Perrone Sibilia M, Sánchez VR, Arcón N, Martin V, Fenoy IM, Goldman A. Contribution of Kazal-Like Domains of the Serine Protease Inhibitor-1 from Toxoplasma gondii in Asthma Therapeutic Vaccination Effectiveness. Int Arch Allergy Immunol 2022; 183:471-478. [PMID: 35016174 DOI: 10.1159/000520796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 11/08/2021] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND We have previously showed rTgPI-1 tolerogenic adjuvant properties in asthma treatment, turning it a promising candidate for allergen-specific immunotherapy. This therapy is an alternative treatment to control asthma that still presents several concerns related to its formulation. rTgPI-1 contains independent inhibitory domains able to inhibit trypsin and neutrophil elastase, both involved in asthma pathology. OBJECTIVES In view of the need to design rational therapies, herein we investigated the contribution of the different inhibitory domains in rTgPI-1 therapeutic effectiveness. METHODS BALB/c mice were rendered allergic by intraperitoneal OVA-alum sensitization and airway challenged. Once the asthmatic phenotype was achieved, mice were intranasally treated with OVA combined with the full-length recombinant protein rTgPI-1 or its truncated versions, Nt (containing trypsin-inhibitory domains) or Ct (containing neutrophil elastase-inhibitory domains). Afterward, mice were aerosol re-challenged. RESULTS Asthmatic mice treated with the neutrophil elastase- or the trypsin-inhibitory domains separately failed to improve allergic lung inflammation. Only when all inhibitory domains were simultaneously administered, an improvement was achieved. Still, a better outcome was obtained when mice were treated with the full-length rTgPI-1. CONCLUSIONS Adjuvant ability depends on the presence of all its inhibitory domains in a single entity, so it should be included in potential asthma treatment formulations as a full-length protein.
Collapse
Affiliation(s)
- Ariadna Soto
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| | - Matías Perrone Sibilia
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| | - Vanesa Roxana Sánchez
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| | - Nadia Arcón
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| | - Valentina Martin
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| | - Ignacio Martín Fenoy
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| | - Alejandra Goldman
- Universidad Nacional de San Martín, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, Buenos Aires, Argentina
| |
Collapse
|
8
|
Wollina U, Schönlebe J, Goldman A. PIGMENTED NODULAR CYSTIC HIDRADENOMA OF THE ANKLE. Georgian Med News 2021:7-9. [PMID: 34365416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Solid-cystic hidradenoma is a benign cutaneous tumor that is most commonly found in the head, neck, trunk, and upper extremity regions of patients in the middle to older aged groups. Presentation on lower extremities and in particular on the foot is uncommon. Nodular hidradenomas represent a dermatological pitfall, being difficult to differentiate from basal cell carcinoma and melanoma. We report on a 53-year-old male patient with a pigmented nodular hidradenoma on his ankle that was surgically removed. We discuss histopathology and differential diagnosis of this eccrine tumor of skin. This is the second reported case in the English literature.
Collapse
Affiliation(s)
- U Wollina
- 1Academic Teaching Hospital, Städtisches Klinikum Dresden, Department of Dermatology and Allergology, Dresden; Germany
| | - J Schönlebe
- 2Institute of Pathology "Georg Schmorl", Städtisches Klinikum Dresden, Academic Teaching Hospital, Dresden, Germany
| | - A Goldman
- 3Clinica Goldman and Hospital Moinhos de Vento, Porto Alegre/ RS, Brazil
| |
Collapse
|
9
|
Goldman A, Wollina U, Machado D, Marinowic D. LONG-PULSED ND:YAG LASER TO TREAT TELANGIECTASIA OF THE NOSE: A COMPREHENSIVE 5-YEAR SINGLE CENTER STUDY. Georgian Med News 2021:7-12. [PMID: 34248020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Telangiectases of the nose are of esthetic concern and treatment is warranted. The study provides the results of 5 years of treatment of telangiectases of the nose region with the long-pulsed Nd:YAG 1,064 nm laser. A retrospective analysis was conducted in patients of Fitzpatrick skin type II-V. Exclusion criteria were patients with a previous history of treatment of the nose region, pregnant or lactating patients or patients with unrealistic expectations regarding the treatment risks, limitations and results. Standardized photographs were obtained before each session and at least 2 months after the last treatment session. A long-pulsed Nd:YAG 1,064 nm laser was used with a spot size of 2.5mm, fluence of 100 - 175 J/cm2, pulse duration of up to 135ms and repetition rate of 2-4 Hz. The follow-up ranged from 2 months to 5 years. The number of laser sessions varied from 1 to 5 monthly. Assessment was made by comparing pre-treatment and post-treatment photographs by two independent specialists and also by the patients' own assessment. All patients presented improvement of the vascular alterations. Evaluation of independent specialists as well as the evaluation of the patients themselves showed a high degree of satisfaction with the treatment. The treatment presented only few transitory side effects. Treatment of telangiectasia on the nose skin with the long-pulsed Nd:YAG 1,064 nm laser demonstrated to be safe and effective even in darker pigmented skin. The major limitation of this study is its retrospective nature.
Collapse
Affiliation(s)
- A Goldman
- 1Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| | - U Wollina
- 2Dresden Municipal Hospital, Academic Teaching Hospital, Department of Dermatology and Allergology, Dresden, Germany
| | - D Machado
- 3Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| | - D Marinowic
- 3Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
10
|
Wollina U, Goldman A. IMPROVEMENT OF HYPERTROPHIC SCARS WITH INTRALESION INJECTIONS OF HYALURONIDASE. Georgian Med News 2020:41-43. [PMID: 32535560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
In contrast to intra-urine wounds, extra-uterine wounds will heal with a scar. A number of conservative and surgical methods have been developed, aiming at improving unsightly and hypertrophic scars. The authors report on their experience with intralesional injection of the enzyme hyaluronidase to improve hypertrophic scars. Hyaluronidase produces low-molecular weight fragments during digestion of high-molecular weight hyaluronic acid. These fragments are known to stimulate angiogenesis and to activate mesenchymal stem cells. The manuscript presents a clinical review of series of patients with hypertrophic scars, mainly resulted from tumor resection, who were treated by this technique.
Collapse
Affiliation(s)
- U Wollina
- 1Dresden Municipal Hospital, Academic Teaching Hospital, Department of Dermatology and Allergology, Germany
| | - A Goldman
- 2Clinica Goldman and Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
11
|
Wollina U, Goldman A. GIANT PEDUNCULATED TUMORS OF SKIN. Georgian Med News 2020:44-49. [PMID: 32535561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The clinical appearance of a skin tumor is of major importance for clinical diagnosis of both benign and malignant neoplasias. Pedunculated growth pattern is unusual to exceptionally rare, depending on a tumor type. A necessary prerequisite for pedunculated growth is a well vascularized stem. We provide a review on large and giant pedunculated tumors of skin to serve as an additional guidance for the clinicians to avoid diagnostic errors and mistreatment. The knowledge of unusual growth pattern of cutaneous neoplasia is an essential not only in outpatient care, but also in care of hospital-admitted patients.
Collapse
Affiliation(s)
- U Wollina
- 1Dresden Municipal Hospital, Academic Teaching Hospital, Department of Dermatology and Allergology, Germany
| | - A Goldman
- 2Clinica Goldman and Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
12
|
Zappia CD, Soto A, Granja‐Galeano G, Fenoy I, Fernandez N, Davio CA, Shayo C, Fitzsimons CP, Goldman A, Monczor F. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model. Pharmacol Res Perspect 2019; 7:e00531. [PMID: 31687162 PMCID: PMC6818730 DOI: 10.1002/prp2.531] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 08/14/2019] [Accepted: 08/15/2019] [Indexed: 12/03/2022] Open
Abstract
Glucocorticoids are among the most effective drugs to treat asthma. However, the severe adverse effects associated generate the need for its therapeutic optimization. Conversely, though histamine is undoubtedly related to asthma development, there is a lack of efficacy of antihistamines in controlling its symptoms, which prevents their clinical application. We have reported that antihistamines potentiate glucocorticoids' responses in vitro and recent observations have indicated that the coadministration of an antihistamine and a synthetic glucocorticoid has synergistic effects on a murine model of allergic rhinitis. Here, the aim of this work is to establish if this therapeutic combination could be beneficial in a murine model of asthma. We used an allergen-induced model of asthma (employing ovalbumin) to evaluate the effects of the synthetic glucocorticoid dexamethasone combined with the antihistamine azelastine. Our results indicate that the cotreatment with azelastine and a suboptimal dose of dexamethasone can improve allergic lung inflammation as shown by a decrease in eosinophils in bronchoalveolar lavage, fewer peribronchial and perivascular infiltrates, and mucin-producing cells. In addition, serum levels of allergen-specific IgE and IgG1 were also reduced, as well as the expression of lung inflammatory-related genes IL-4, IL-5, Muc5AC, and Arginase I. The potentiation of dexamethasone effects by azelastine could allow to reduce the effective glucocorticoid dose needed to achieve a therapeutic effect. These findings provide first new insights into the potential benefits of glucocorticoids and antihistamines combination for the treatment of asthma and grants further research to evaluate this approach in other related inflammatory conditions.
Collapse
Affiliation(s)
- Carlos D. Zappia
- Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina
- Instituto de Investigaciones Farmacológicas (ININFA)CONICET – Universidad de Buenos AiresBuenos AiresArgentina
| | - Ariadna Soto
- Centro de Estudios en Salud y Medio Ambiente (CESyMA)Escuela de Ciencia y TecnologíaUniversidad Nacional de San Martín – CONICETBuenos AiresArgentina
| | - Gina Granja‐Galeano
- Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina
- Instituto de Investigaciones Farmacológicas (ININFA)CONICET – Universidad de Buenos AiresBuenos AiresArgentina
| | - Ignacio Fenoy
- Centro de Estudios en Salud y Medio Ambiente (CESyMA)Escuela de Ciencia y TecnologíaUniversidad Nacional de San Martín – CONICETBuenos AiresArgentina
| | - Natalia Fernandez
- Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina
- Instituto de Investigaciones Farmacológicas (ININFA)CONICET – Universidad de Buenos AiresBuenos AiresArgentina
| | - Carlos A. Davio
- Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina
- Instituto de Investigaciones Farmacológicas (ININFA)CONICET – Universidad de Buenos AiresBuenos AiresArgentina
| | - Carina Shayo
- Laboratorio de Patología y Farmacología MolecularInstituto de Biología y Medicina Experimental CONICETBuenos AiresArgentina
| | - Carlos P. Fitzsimons
- Center for NeuroscienceSwammerdam Institute for Life SciencesFaculty of ScienceUniversity of AmsterdamAmsterdamThe Netherlands
| | - Alejandra Goldman
- Centro de Estudios en Salud y Medio Ambiente (CESyMA)Escuela de Ciencia y TecnologíaUniversidad Nacional de San Martín – CONICETBuenos AiresArgentina
| | - Federico Monczor
- Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina
- Instituto de Investigaciones Farmacológicas (ININFA)CONICET – Universidad de Buenos AiresBuenos AiresArgentina
| |
Collapse
|
13
|
Perrone Sibilia MD, Aldirico MDLÄ, Soto AS, Picchio MS, Sánchez VR, Arcón N, Moretta R, Martín V, Vanzulli S, Fenoy IM, Goldman A. Chronic infection with the protozoan Toxoplasma gondii prevents the development of experimental atopic dermatitis in mice. J Dermatol Sci 2019; 96:143-150. [PMID: 31735466 DOI: 10.1016/j.jdermsci.2019.10.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 10/04/2019] [Accepted: 10/27/2019] [Indexed: 11/26/2022]
Abstract
BACKGROUND Supporting the hypothesis thatT. gondii infection protects against allergy in humans we previously demonstrated that this infection can modulate not only the susceptibility to develop respiratory allergies in mice but also suppresses allergic responses at systemic level. This latter finding suggests that T. gondii infection could prevent the onset of other allergic diseases, such as atopic dermatitis. At present, few studies have investigated the modulation of atopic dermatitis by parasite infections. OBJECTIVE Here, we sought to investigate whether chronic infection with T. gondii is capable of modulating the development of atopic dermatitis. METHODS Chronically infected mice were sensitized by repeated epicutaneous ovalbumin administration. Skin histopathology, humoral response, cytokine production and innate type-II lymphoid cells (ILC2) were assessed. RESULTS A marked reduction in epidermal thickness and dermal inflammatory infiltrate along with a reduction in mast cell count was observed in infected mice compared to non-infected mice. These results correlated with a diminished TH2 and TH1 allergen specific response. Reduced type-II IL-4 and IL-5 cytokines were already detected during the first 24 h of allergen sensitization in splenocytes and draining lymph nodes from infected mice. Moreover, this reduced type-II profile in chronically infected animals correlated with diminished ILC2 number in draining lymph nodes. CONCLUSION Chronic infection withT. gondii prevents the development of atopic dermatitis. The diminished susceptibility seems to result from changes in type-II innate immune response that may lead to the induction of a deficient TH2 response and consequently to a lower susceptibility to develop atopic dermatitis.
Collapse
Affiliation(s)
- Matías Damián Perrone Sibilia
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - María de Los Ängeles Aldirico
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Ariadna Soledad Soto
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Mariano Sergio Picchio
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Vanesa Roxana Sánchez
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Nadia Arcón
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Rosalía Moretta
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Valentina Martín
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Silvia Vanzulli
- Laboratorio de Anatomía Patológica, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Ignacio Martín Fenoy
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina
| | - Alejandra Goldman
- Universidad Nacional de San Martín, CONICET, Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, ECyT, San Martín, Argentina.
| |
Collapse
|
14
|
Goldman A, Siegel S, Partridge J. Improving Patient Outcomes & Decreasing Hospital Costs Through Nutrition. J Acad Nutr Diet 2019. [DOI: 10.1016/j.jand.2019.06.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Smalley M, Alam N, Murmu N, Somashekhar S, Ulaganathan B, Thayakumar A, Maciejko L, Ganesh J, Lawson M, Gertje H, Shanthappa BU, Goldman A. Abstract P6-07-03: A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Outgrowth of new blood vessels (neovascularization) allows tumors to supply themselves with oxygen and nutrients, and to rapidly metastasize throughout the body. Triple negative breast cancer (TNBC) is particularly susceptible to neovascularization. However, success with anti-angiogenics is highly variable and often patient-specific. This is particularly true as anti-angiogenics are being combined with immunotherapies. Thus, there is a huge unmet need for clinicians to test and predict clinical efficacy of anti-angiogenics at the individual patient level, prior to treatment.
Methods: Here, we characterize a patient-autologous, ex-vivo tumor model, termed CANscript, as a platform to study the intratumor microvascular density (iMVD) of breast cancer samples (N=15). To profile iMVD we used immunohistochemical (IHC) analysis of CD34, an early biomarker of neovascularization. We then introduced anticancer and anti-angiogenic agents (e.g. Avastin) for 72 hours, and subsequently quantified phenotypic response to drugs by testing viability, cell death, proliferation and morphology. These quantitative data were then fed into a machine learning algorithm that provides a clinical response prediction (M-Score).
Results: We determined that ex-vivo culture reliably retains baseline heterogeneity of iMVD based on expression of CD34+ nodes per visual field by IHC. Furthermore, we show that anticancer and anti-angiogenic agents will dynamically alter iMVD, ex-vivo, in a patient-specific manner. Finally, we show that prediction of clinical response using the 'M-Score' algorithm associates with diminished expression of CD34 per visual field of IHC after drug pressure.
Summary: Neovascularization and iMVD are features of aggressive cancers, such as TNBC. CANscript provides a rapid assessment of clinical response to anticancer drugs, many of which induce their antitumor effect by targeting the tumor vasculature. We show that pharmacodynamics of antiangiogenics can be captured during acute ex-vivo culture under drug pressure, which associate to clinical response prediction. Therefore, we highlight the ability of CANscript as a platform to predict clinical response to anti-angiogenic drugs, and may therefore be a logical 'testing ground' to predict clinical efficacy of antiangiogenic drugs combined with immunotherapies.
Citation Format: Smalley M, Alam N, Murmu N, Somashekhar S, Ulaganathan B, Thayakumar A, Maciejko L, Ganesh J, Lawson M, Gertje H, Shanthappa BU, Goldman A. A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-07-03.
Collapse
Affiliation(s)
- M Smalley
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - N Alam
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - N Murmu
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - S Somashekhar
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - B Ulaganathan
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - A Thayakumar
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - L Maciejko
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - J Ganesh
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - M Lawson
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - H Gertje
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - BU Shanthappa
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| | - A Goldman
- Mitra Biotech, Woburn, MA; Chittaranjan National Cancer Institute, Kolkata, West Bengal, India; Manipal Hospitals, Bengarulu, Karnataka, India
| |
Collapse
|
16
|
Siegel S, Fan L, Goldman A, Higgins J, Goates S, Partridge J. The Impact of Hospital Quality Improvement Initiatives on Health Outcomes. J Acad Nutr Diet 2018. [DOI: 10.1016/j.jand.2018.06.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Goldman A, Staub H, Wollina U. HYPERCALCEMIA DUE TO POLYMETHYLMETHACRYLATE INJECTIONS? (LITERATURE REVIEW AND CASE REPORTS). Georgian Med News 2018:17-20. [PMID: 30358533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Hypercalcemia is a common feature of malignancy, bone metabolic conditions and granulomatous disorders. In the latter, hypercalcemia is usually calcitriol-related. As eventual association of silicone and polymethylmethacrylate (PMMA) injections with granulomatous disease and hypercalcemia the condition has become an issue of recent interest. Authors report on two cases of calcitriol-related hypercalcemia where PMMA injections had been previously administered. The association, even though intriguing, requires additional confirmation by follow-up studies.
Collapse
Affiliation(s)
- A Goldman
- Clinica Goldman and Hospital Moinhos de Vento, Porto Alegre; Department of Rheumatology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| | - H Staub
- Clinica Goldman and Hospital Moinhos de Vento, Porto Alegre; Department of Rheumatology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| | - U Wollina
- Clinica Goldman and Hospital Moinhos de Vento, Porto Alegre; Department of Rheumatology, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| |
Collapse
|
18
|
Trautman CL, Palmer WC, Taner CB, Canabal JM, Getz T, Goldman A, Heckman MG, Diehl NN, Lee DD, Stancampiano FF. Thromboelastography as a Predictor of Outcomes Following Liver Transplantation. Transplant Proc 2018; 49:2110-2116. [PMID: 29149970 DOI: 10.1016/j.transproceed.2017.07.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Revised: 06/12/2017] [Accepted: 07/30/2017] [Indexed: 12/17/2022]
Abstract
BACKGROUND Thromboelastography (TEG) has been used perioperatively during liver transplantation (LT) to provide a real-time global hemostasis assessment for targeted blood product replacement. We aimed to analyze the relationship between post-LT TEG results and outcomes. METHODS We retrospectively analyzed patients undergoing LT from November 2008 to December 2014 at Mayo Clinic Florida. All 441 single-organ 1st-time LT patients aged ≥18 years requiring post-LT intensive care unit management were included. TEG parameters including r time, k time, α angle, and maximum amplitude were measured regularly during the first 24 hours after LT. Outcomes included return to the operating room secondary to bleeding, length of hospitalization, survival, and early allograft dysfunction. RESULTS A prolonged and/or lengthening r time, k time, and r+k time were all independently associated with increased length of hospitalization after LT. Increased maximum amplitude on the first post-LT TEG was associated with early allograft dysfunction. No notable associations of TEG parameters with survival or return to operating room were observed. CONCLUSIONS The association of absolute and temporal TEG value changes with increased length of hospitalization and early allograft dysfunction suggests that TEG may have a role in identifying patients at high risk for these outcomes.
Collapse
Affiliation(s)
- C L Trautman
- Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida
| | - W C Palmer
- Gastroenterology, Mayo Clinic, Jacksonville, Florida.
| | - C B Taner
- Transplant, Mayo Clinic, Jacksonville, Florida
| | - J M Canabal
- Transplant, Mayo Clinic, Jacksonville, Florida
| | - T Getz
- Clinical Research Internship Study Program, Mayo Clinic, Jacksonville, Florida
| | - A Goldman
- Clinical Research Internship Study Program, Mayo Clinic, Jacksonville, Florida
| | - M G Heckman
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida
| | - N N Diehl
- Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida
| | - D D Lee
- Transplant, Mayo Clinic, Jacksonville, Florida
| | - F F Stancampiano
- Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida
| |
Collapse
|
19
|
Smalley M, Shanthappa BU, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, Maciejko L, Radhakrishnan P, Biswas M, Thiyagarajan S, Majumder B, Gopinath KS, K GB, Goldman A. Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-11-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised of malignant cells, normal stroma, soluble ligands, and tumor-immune contexture; attributes that are unique to each individual patient. This is particularly true for emerging anticancer drugs, such as immune checkpoint inhibitors, which recalibrate the body's own immune defense largely by modulating exhaustion of cytotoxic lymphocytes including T cells and natural killer (NK) cells. However, clinical response to therapy varies enormously. There is a critical gap in our understanding for the mechanisms that drive response or resistance to conventional drugs and immunotherapies at the individual patient level.
Methods: Here, we used a fully patient-autologous, clinically-validated ex-vivo tumor model that recreates and preserves the native, patient tumor microenvironment (CANscriptTM), which incorporates an algorithm-driven method to predict clinical response to therapy (M-Score). Utilizing tissue from patients diagnosed with luminal, HER2 positive, and triple-negative (ER- PR- HER2-) breast cancers (N=10), we studied phenotypic alterations to the tumor-immune contexture under pressure of conventional standard-of-care regimens and immunotherapies including immune-checkpoint inhibitors, ex-vivo. To do this, we used a comprehensive panel of immunological assays to evaluate changes in cytotoxic lymphocytes by flow cytometry and multiplex immunohistochemistry (i.e. CD56, MHC class 1A/B, NKG2D/C, CD8, CD3, PD-1, CTLA-4, TIM-3, LAG-3, 4-1BB, granzyme A/B). In addition, we used multiplex cytokine analysis to study the soluble components of the tumor microenvironment.
Results: We identified that tumor response, predicted by M-Score, correlates to increased infiltration of NK cells, which associated a pro-inflammatory cytokine signature from the tumor microenvironment. Interestingly, these evidences were concordant with induction of the tumor-expressing biomarker MICA/B, which is known to attract and recruit active NK cells. Furthermore, we determined that therapy-induced expression of protein biomarkers associated with NK cell exhaustion inversely correlated to the expression of cytotoxic granzyme B in the tumor microenvironment.
Conclusions: Taken together, these data demonstrate an integral role that NK cells contribute to the antitumor effect of therapy including conventional and immuno-modulatory drugs. It further demonstrates how a novel ex-vivo platform can be harnessed to study the mechanisms of response and resistance, which couldn't otherwise be known in a drug naïve state. Such an advance in our preclinical methods to study anticancer drugs at the individual patient level can help guide treatment decisions for clinicians while simultaneously functioning as a platform to study clinical efficacy of novel and emerging agents.
Citation Format: Smalley M, Shanthappa BU, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, Maciejko L, Radhakrishnan P, Biswas M, Thiyagarajan S, Majumder B, Gopinath KS, K GB, Goldman A. Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-11-04.
Collapse
Affiliation(s)
- M Smalley
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - BU Shanthappa
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - H Gertje
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - M Lawson
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - B Ulaganathan
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - A Thayakumar
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - L Maciejko
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - P Radhakrishnan
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - M Biswas
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - S Thiyagarajan
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - B Majumder
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - KS Gopinath
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - GB K
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| | - A Goldman
- Integrative Immuno-Oncology Center Mitra RxDx Inc., Woburn, MA; Mitra RxDx, Bangalore, Karnataka, India; Bangalore Institute of Oncology, Bangalore, Karnataka, India; Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India
| |
Collapse
|
20
|
Goldman A, Wollina U. UNILATERAL FRONTALIS MUSCLE PARALYSIS: MANAGEMENT WITH BOTULINUM TOXIN A (CASE REPORTS). Georgian Med News 2018:73-77. [PMID: 29578428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Unilateral frontalis muscle palsy is a debilitating disease with a heterogeneous etiology. Congenital or acquired unilateral paralysis of the frontalis muscle causes ipsilateral brow ptosis and contralateral hypermobility of the non-paralytic frontalis muscle, resulting in a bizarre asymmetry and emotional embarrassment. We present five patients with unilateral frontal muscle paralysis, two males and three females, aged between 32 and 68, treated with botulinum toxin A injection to the contralateral (non-affected) side. A total dose between 10 to 30 U botulinum toxin A (onabotulinum or incobotulinum toxin A) successfully improve symmetry and facial esthetics without any adverse events. Botulinum toxin A is an alternative to facial palsy surgery but may also be used as an adjunct after the surgical procedure to optimize the outcome.
Collapse
Affiliation(s)
- A Goldman
- Clinica Goldman, Porto Alegre, Rio Grande do Sul, Brazil; Department of Dermatology and Allergology, Municipal Hospital Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| | - U Wollina
- Clinica Goldman, Porto Alegre, Rio Grande do Sul, Brazil; Department of Dermatology and Allergology, Municipal Hospital Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| |
Collapse
|
21
|
Picchio MS, Sánchez VR, Arcon N, Soto AS, Perrone Sibilia M, Aldirico MDLA, Urrutia M, Moretta R, Fenoy IM, Goldman A, Martin V. Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice. Exp Parasitol 2018; 185:62-70. [DOI: 10.1016/j.exppara.2018.01.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 10/23/2017] [Accepted: 01/03/2018] [Indexed: 12/23/2022]
|
22
|
Goldman A, Wollina U. KERATOACANTHOMA OF THE UPPER LIP: REVIEW OF THE LITERATURE AND REPORT OF CASE WITH CENTRAL UPPER LIP RECONSTRUCTION. Georgian Med News 2018:77-80. [PMID: 29578429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Keratoakanthoma (KA) is a common non-melanoma skin tumor of sun-exposed skin. Recently it has been classified as a highly differentiated squamous cell carcinoma, based on the evidence of local destruction, tissue invasion and malignant transformation with metastatic spread described in the medical literature. Lower lip KA is not uncommon on lower lip, and quite rare on upper lip. The authors present a case of 78-year-old Caucasian male patient with a rapidly growing keratotic tumor of the central region of upper lip. After complete surgical excision, single-stage reconstruction of the defect was performed by modified Goldstein's bilateral advancement myocutaneous vermilion flap. The histologic examination confirmed KA with excision margins within healthy tissue. Healing was unremarkable and functional and esthetic outcomes were very good. KA of the upper lip is a rare tumor that warrants complete surgical excision. Reconstruction of the central part of the upper lip is a challenge, but bilateral advancement myocutaneous vermilion flap resulted in good outcome.
Collapse
Affiliation(s)
- A Goldman
- Clinica Goldman, Porto Alegre, Rio Grande do Sul, Brazil; Department of Dermatology and Allergology, Municipal Hospital Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| | - U Wollina
- Clinica Goldman, Porto Alegre, Rio Grande do Sul, Brazil; Department of Dermatology and Allergology, Municipal Hospital Dresden, Academic Teaching Hospital of the Technical University of Dresden, Germany
| |
Collapse
|
23
|
Smalley M, Shanthappa B, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, Maciejko L, Radhakrishnan P, Biswas M, Thiyagarajan S, Majumder B, Gopinath K, Babu G, Goldman A. Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx711.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Soto AS, Fenoy IM, Sanchez VR, March F, Perrone Sibilia MD, Aldirico MDLA, Picchio MS, Arcon N, Acosta PL, Polack FP, Martin V, Goldman A. Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy. PLoS One 2017; 12:e0187002. [PMID: 29073215 PMCID: PMC5658115 DOI: 10.1371/journal.pone.0187002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 10/11/2017] [Indexed: 11/25/2022] Open
Abstract
Serine-proteases are important players in the pathogenesis of asthma, promoting inflammation and tissue remodeling. It’s also known that many serine protease inhibitors display immunomodulatory properties. TgPI-1 is a Toxoplasma gondii protein that exhibits broad spectrum inhibitory activity against serine proteases. In view of the increased prevalence of atopic disorders and the need to develop new treatment strategies we sought to investigate the potential of TgPI-1 for treating respiratory allergies. For this purpose, we developed a therapeutic experimental model. BALB/c mice were rendered allergic by intraperitoneal ovalbumin-alum sensitization and airway-challenged. Once the asthmatic phenotype was achieved, mice were intranasally treated with rTgPI-1 alone or with a mixture of rTgPI-1 and ovalbumin (OVA). A week later mice were given a secondary aerosol challenge. Treatment with rTgPI-1 alone or co-administered with OVA diminished bronchoalveolar eosinophilia, mucus production and peribronchial lung infiltration. This effect was accompanied by a lung resistance reduction of 26.3% and 50.3% respectively. Both treatments resulted in the production of lower levels of IL-4, IL-5, IFN-γ and regulatory IL-10 by thoracic lymph node cells stimulated with OVA. Interestingly, significant decreases in OVA specific IgE and T cell proliferation, and increases in FoxP3+ T cells at local and systemic levels were only detected when the inhibitor was administered along with OVA. These results show that both rTgPI-1 treatments reduced asthma hallmarks. However, co-administration of the inhibitor with the allergen was more effective. Hence, rTgPI-1 emerges as a novel adjuvant candidate for asthma treatment.
Collapse
Affiliation(s)
- Ariadna S. Soto
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Ignacio M. Fenoy
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Vanesa R. Sanchez
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Florencia March
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
| | - Matías D. Perrone Sibilia
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
| | - María de los Angeles Aldirico
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
| | - Mariano S. Picchio
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Nadia Arcon
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Patricio L. Acosta
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Fundación Infant, Buenos Aires, Argentina
| | | | - Valentina Martin
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - Alejandra Goldman
- Laboratorio de Inmunología, Vacunas y Alergia, CESyMA, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Buenos Aires, Argentina
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- * E-mail:
| |
Collapse
|
25
|
Goldman A, Wollina U. MIXED TYPE BASAL CELL CARCINOMA OF THE AURICLE - SINGLE STAGE RECONSTRUCTION AFTER R0-RESECTION BY A MODIFIED ANTIA-BUCH FLAP (CLINICAL CASE REPORT). Georgian Med News 2017:7-10. [PMID: 28972475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Basal cell carcinoma (BCC) is the most common neoplasia in Caucasians with a pre-dominance for the sun-exposed anatomical areas including the auricle. The treatment of choice is surgery achieving an R0-resection status. On the other hand, functional and aesthetic results are of importance. We report a case of 79-year-old Caucasian man with a BCC of the helical rim that was treated surgically using a modified Antia-Buch flap for single stage reconstruction. Article is discussing peculiarities of BCC on the auricle and options for auricular reconstruction.
Collapse
Affiliation(s)
- A Goldman
- Clinica Goldman, Porto Alegre, RS, Brazil; Department of Dermatology and Allergology, Academic Teaching Hospital Dresden, Dresden, Germany
| | - U Wollina
- Clinica Goldman, Porto Alegre, RS, Brazil; Department of Dermatology and Allergology, Academic Teaching Hospital Dresden, Dresden, Germany
| |
Collapse
|
26
|
Goldman A, Majumder B, Dhawan A, Kohandel M, Majumder P, Sengupta S. Abstract P3-03-18: An ex-vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-03-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer cells undergo phenotypic cell state transitions in response to chemotherapy as a mechanism that can confer transient resistance. However, such cell state transitions can also unlock unique vulnerabilities that can be exploited using temporally-sequenced combination chemotherapy. Here, utilizing a primary breast cancer ex-vivo functional assay that captures tumor heterogeneity, we report that in response to a chemotherapeutic agent, a subset of cancer cells can mount an acutely-induced phenotypic adaptive resistance to future cytotoxic pressure via the transient acquisition of a unique metabolic state defined by augmented glycolysis together with mitochondrial proficiency. These cells activate two complex, temporally-interdependent pathways that enable a glucose shunt towards the pentose phosphate pathway (PPP), which confers an adaptive cross-tolerance to different chemotherapeutic agents. Mathematically modeling these pathways, and simulating drug schedules, we define a rationally-designed 3-drug combination therapy of metabolic inhibitors and cytotoxic agents, which results in improved cancer survival. Our findings highlight a new bioenergetics-based adaptive resistance mechanism through which cancer cells can survive combinations of chemotherapy. Administration of metabolic inhibitors in rational, temporal sequence with existing chemotherapy can emerge as a new paradigm in the treatment of cancer.
Citation Format: Goldman A, Majumder B, Dhawan A, Kohandel M, Majumder P, Sengupta S. An ex-vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-03-18.
Collapse
Affiliation(s)
- A Goldman
- Mitra Biotechnology, Woburn, MA; University of Waterloo; Harvard Medical School
| | - B Majumder
- Mitra Biotechnology, Woburn, MA; University of Waterloo; Harvard Medical School
| | - A Dhawan
- Mitra Biotechnology, Woburn, MA; University of Waterloo; Harvard Medical School
| | - M Kohandel
- Mitra Biotechnology, Woburn, MA; University of Waterloo; Harvard Medical School
| | - P Majumder
- Mitra Biotechnology, Woburn, MA; University of Waterloo; Harvard Medical School
| | - S Sengupta
- Mitra Biotechnology, Woburn, MA; University of Waterloo; Harvard Medical School
| |
Collapse
|
27
|
Goldman A, Wollina U, Tchernev G, Chokoeva AA, Lotti T. Medium-sized congenital melanocytic nevus of the forehead, glabella and temple surgical treatment and long-term follow-up. J BIOL REG HOMEOS AG 2016; 30:53-58. [PMID: 27373136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Congenital melanocytic nevi can be stigmatising for the patient. Larger nevi bear an increased risk for melanoma development. Large congenital melanocytic nevi may be a symptom of neurocutaneous melanosis. We report on a 5-year-old boy with an extensive hair-bearing facial congenital melanocytic nevus, covering forehead, glabella and temple region associated with unilateral brow and blepharoptosis. The lesion was excised en bloc. The resulting defect had been closed by full thickness skin graft. Healing was unremarkable and long-term follow-up over 13 years demonstrated a satisfying esthetic and functional outcome. There was no evidence of melanoma development. Surgery is an option for disfiguring larger congenital melanocytic nevi as long as esthetics and function can be preserved. Long-term follow-up is recommended due to the increased risk of melanoma.
Collapse
Affiliation(s)
- A Goldman
- Clinica Goldman, Porto Alegre/RS, Brazil
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR-Sofia), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - A A Chokoeva
- Onkoderma- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical Faculty, Plovdiv, Bulgaria
| | - T Lotti
- Department of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
28
|
Wollina U, Goldman A. [Esthetic dermatology for the elderly]. Hautarzt 2015; 67:148-52. [PMID: 26452352 DOI: 10.1007/s00105-015-3700-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Esthetic dermatology discovers older age. Methods and techniques which are useful in younger people need modifications to meet the special needs of the elderly. These aspects are discussed with a focus on the aging face. Esthetic dermatology is most successful when using principles of regenerative medicine.
Collapse
Affiliation(s)
- U Wollina
- Klinik für Dermatologie und Allergologie, Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum, Akademisches Lehrkrankenhaus der TU Dresden, Friedrichstr. 41, 01067, Dresden, Deutschland.
| | - A Goldman
- Clinica Goldman, Porto Alegre, RS, Brasilien
| |
Collapse
|
29
|
Sánchez VR, Fenoy IM, Picchio MS, Soto AS, Arcon N, Goldman A, Martin V. Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection. Acta Trop 2015. [PMID: 26200784 DOI: 10.1016/j.actatropica.2015.07.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Subunit-based vaccines are safer than live or attenuated pathogen vaccines, although they are generally weak immunogens. Thus, proper combination of immunization strategies and adjuvants are needed to increase their efficacy. We have previously protected C3H/HeN mice from Toxoplasma gondii infection by immunization with the serine protease inhibitor-1 (TgPI-1) in combination with alum. In this work, we explore an original vaccination protocol that combines administration of recombinant TgPI-1 by intradermal and intranasal routes in order to enhance protection in the highly susceptible C57BL/6 strain. Mice primed intradermally with rTgPI-1 plus alum and boosted intranasally with rTgPI-1 plus CpG-ODN elicited a strong specific Th1/Th2 humoral response, along with a mucosal immune response characterized by specific-IgA in intestinal lavages. A positive cellular response of mesentheric lymph node cells and Th1/Th2 cytokine secretion in the ileon were also detected. When immunized mice were challenged with the cystogenic Me49 T. gondii strain, they displayed up to 62% reduction in brain parasite burden. Moreover, adoptive transfer of mesenteric lymph node cells from vaccinated to naïve mice induced significant protection against infection. These results demonstrate that this strategy that combines the administration of TgPI-1 by two different routes, intradermal priming and intranasal boost, improves protective immunity against T. gondii chronic infection in highly susceptible mice.
Collapse
|
30
|
Fenoy IM, Sánchez VR, Soto AS, Picchio MS, Martin V, Goldman A. Toxoplasma gondii infection modulate systemic allergic immune response in BALB/c mice. Exp Parasitol 2015; 154:47-50. [DOI: 10.1016/j.exppara.2015.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 03/19/2015] [Accepted: 04/08/2015] [Indexed: 11/29/2022]
|
31
|
Goldman A, Gordon I, Pritchard J, Kemshead J. A monoclonal antibody, UJ13A, used for radioimmunolocalisation of neuroblastoma in an animal model and patients. Prog Exp Tumor Res 2015; 29:85-92. [PMID: 4070639 DOI: 10.1159/000411628] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
32
|
Fenoy IM, Sanchez VR, Soto AS, Picchio MS, Maglioco A, Corigliano MG, Dran GI, Martin V, Goldman A. Regulatory cells induced by acute toxoplasmosis prevent the development of allergic lung inflammation. Immunobiology 2014; 220:641-8. [PMID: 25532793 DOI: 10.1016/j.imbio.2014.11.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Revised: 11/18/2014] [Accepted: 11/22/2014] [Indexed: 01/31/2023]
Abstract
The increased prevalence of allergies in developed countries has been attributed to a reduction of some infections. Supporting epidemiological studies, we previously showed that both acute and chronic Toxoplasma gondii infection can diminish allergic airway inflammation in BALB/c mice. The mechanisms involved when sensitization occurs during acute phase would be related to the strong Th1 response induced by the parasite. Here, we further investigated the mechanisms involved in T. gondii allergy protection in mice sensitized during acute T. gondii infection. Adoptive transference assays and ex vivo co-cultures experiments showed that not only thoracic lymph node cells from infected and sensitized mice but also from non-sensitized infected animals diminished both allergic lung inflammation and the proliferation of effector T cells from allergic mice. This ability was found to be contact-independent and correlated with high levels of CD4(+)FoxP3(+) cells. IL-10 would not be involved in allergy suppression since IL-10-deficient mice behaved similar to wild type mice. Our results extend earlier work and show that, in addition to immune deviation, acute T. gondii infection can suppress allergic airway inflammation through immune suppression.
Collapse
Affiliation(s)
- Ignacio M Fenoy
- Laboratorio de Inmunología, vacunas y alergia, CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Vanesa R Sanchez
- Laboratorio de Inmunología, vacunas y alergia, CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Ariadna S Soto
- Laboratorio de Inmunología, vacunas y alergia, CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Mariano S Picchio
- Laboratorio de Inmunología, vacunas y alergia, CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Andrea Maglioco
- Instituto de Medicina Experimental (IMEX-CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Mariana G Corigliano
- Laboratorio de Biotecnología Vegetal, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina
| | - Graciela I Dran
- Instituto de Medicina Experimental (IMEX-CONICET), Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Valentina Martin
- Laboratorio de Inmunología, vacunas y alergia, CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Alejandra Goldman
- Laboratorio de Inmunología, vacunas y alergia, CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina.
| |
Collapse
|
33
|
Goldman A, Eggen B, Golding B, Murray V. The health impacts of windstorms: a systematic literature review. Public Health 2014; 128:3-28. [DOI: 10.1016/j.puhe.2013.09.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Revised: 09/26/2013] [Accepted: 09/30/2013] [Indexed: 10/26/2022]
|
34
|
Corigliano MG, Fenoy I, Sander V, Maglioco A, Goldman A, Clemente M. Plant heat shock protein 90 as carrier-adjuvant for immunization against a reporter antigen. Vaccine 2013; 31:5872-8. [PMID: 24120680 DOI: 10.1016/j.vaccine.2013.09.047] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 08/31/2013] [Accepted: 09/23/2013] [Indexed: 02/04/2023]
Abstract
Here, we evaluated the modulation of the immune response induced by Hsp90 of Nicotiana benthamiana (NbHsp90.3) against the Maltose Binding Protein (MBP) as a reporter antigen. Equimolar quantities of recombinant proteins were administered in mice as follows: MBP alone (MBP group), a mixture of MBP and rNbHsp90.3 (MBP+rNbHsp90.3 group) and the fusion of MBP to rNbHsp90.3 (MBP-rNbHsp90.3 group). The covalent linkage between NbHsp90.3 and MBP to bring a fusion protein was essential to induce the strong specific antibody response with predominance of IgG2a. Eighty-four days after the first immunization, splenocyte proliferation from MBP-rNbHsp90.3-immunized mice was consistently higher than that from MBP and MBP+rNbHsp90.3 groups. In addition, splenocytes from MBP-rNbHsp90.3 immunized mice produced higher levels of IFN-γ than controls. Finally, both formulations with rNbHsp90.3 significantly enhanced the MHC class I expression levels, but only rNbHsp90.3 covalent bound to MBP induced a specific cellular immune response against MBP measured as increased percentage of CD8(+) T cells. Taken together, these results suggest that plant HSP90s could be incorporated as adjuvants in vaccines that require the generation of a Th1 response along with a CD8 cytotoxic cell response to confer immunity.
Collapse
Affiliation(s)
- Mariana G Corigliano
- Laboratorio de Biotecnología Vegetal, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina
| | | | | | | | | | | |
Collapse
|
35
|
Meri T, Amdahl H, Lehtinen MJ, Hyvärinen S, McDowell JV, Bhattacharjee A, Meri S, Marconi R, Goldman A, Jokiranta TS. Microbes bind complement inhibitor factor H via a common site. PLoS Pathog 2013; 9:e1003308. [PMID: 23637600 PMCID: PMC3630169 DOI: 10.1371/journal.ppat.1003308] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2012] [Accepted: 03/02/2013] [Indexed: 11/18/2022] Open
Abstract
To cause infections microbes need to evade host defense systems, one of these being the evolutionarily old and important arm of innate immunity, the alternative pathway of complement. It can attack all kinds of targets and is tightly controlled in plasma and on host cells by plasma complement regulator factor H (FH). FH binds simultaneously to host cell surface structures such as heparin or glycosaminoglycans via domain 20 and to the main complement opsonin C3b via domain 19. Many pathogenic microbes protect themselves from complement by recruiting host FH. We analyzed how and why different microbes bind FH via domains 19–20 (FH19-20). We used a selection of FH19-20 point mutants to reveal the binding sites of several microbial proteins and whole microbes (Haemophilus influenzae, Bordetella pertussis, Pseudomonas aeruginosa, Streptococcus pneumonia, Candida albicans, Borrelia burgdorferi, and Borrelia hermsii). We show that all studied microbes use the same binding region located on one side of domain 20. Binding of FH to the microbial proteins was inhibited with heparin showing that the common microbial binding site overlaps with the heparin site needed for efficient binding of FH to host cells. Surprisingly, the microbial proteins enhanced binding of FH19-20 to C3b and down-regulation of complement activation. We show that this is caused by formation of a tripartite complex between the microbial protein, FH, and C3b. In this study we reveal that seven microbes representing different phyla utilize a common binding site on the domain 20 of FH for complement evasion. Binding via this site not only mimics the glycosaminoglycans of the host cells, but also enhances function of FH on the microbial surfaces via the novel mechanism of tripartite complex formation. This is a unique example of convergent evolution resulting in enhanced immune evasion of important pathogens via utilization of a “superevasion site.” Complement is an important arm of innate immunity. Activation of this plasma protein cascade leads to opsonization of targets for phagocytosis, direct lysis of Gram-negative bacteria, and enhancement of the inflammatory and acquired immune responses. No specific signal is needed for activation of the alternative pathway of complement, leading to its activation on all unprotected surfaces. Pathogenic microbes need to evade this pathway, and several species are known to recruit host complement inhibitor factor H (FH) to prevent the activation. FH is important for protection of host cells, too, as defects in FH lead to a severe autoreactive disease, atypical hemolytic uremic syndrome. We have now identified at the molecular level a common mechanism by which seven different microbes, Haemophilus influenzae, Bordetella pertussis, Pseudomonas aeruginosa, Streptococcus pneumoniae, Candida albicans, Borrelia burgdorferi and B. hermsii, recruit FH. All microbes bind FH via a common site on domain 20, which facilitates formation of a tripartite complex between the microbial protein, the main complement opsonin C3b, and FH. We show that, by utilizing the common microbial binding site on FH20, microbes can inhibit complement more efficiently. This detailed knowledge on mechanism of complement evasion can be used in developing novel antimicrobial chemotherapy.
Collapse
Affiliation(s)
- T Meri
- Haartman Institute, Department of Bacteriology and Immunology and Immunobiology Research Program, University of Helsinki, Helsinki, Finland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Aesthetic medicine has become increasingly popular in the last two decades. The same trend has occurred in dermatology. Aesthetic dermatology prefers minimally invasive procedures. Nevertheless, even these procedures are not free of possible adverse effects. The spectrum of possible adverse effects, their management and prevention are discussed for four popular procedures in aesthetic dermatology, i.e. chemical peels, mesotherapy, botulinum toxin, and dermal fillers. Aesthetic procedures should only be performed by well-educated, well-trained medical doctors with an excellent medical background, never by lay persons.
Collapse
Affiliation(s)
- U Wollina
- Klinik für Dermatologie und Allergologie, Krankenhaus Dresden-Friedrichstadt - Städtisches Klinikum, Akademisches Lehrkrankenhaus der TU Dresden, Friedrichstr. 41, 01067 Dresden.
| | | | | |
Collapse
|
37
|
Goldman A, Murcray FJ, Murcray DG, Kosters JJ, Rinsland CP, Flaud JM, Camy-Peyret C, Barbe A. Isotopic abundances of stratopheric ozone from balloon-borne high-resolution infrared solar spectra. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/jd094id06p08467] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
38
|
Rinsland CP, Goldman A, Murcray DG, Murcray FJ, Bonomo FS, Blatherwick RD, Devi VM, Smith MAH, Rinsland PL. Tentative identification of the 780-cm−1ν4bandQbranch of chlorine nitrate in high-resolution solar absorption spectra of the stratosphere. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/jd090id05p07931] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
39
|
Goldman A, Murcray FJ, Blatherwick RD, Kosters JJ, Murcray FH, Murcray DG, Rinsland CP. New spectral features of stratospheric trace gases identified from high-resolution infrared balloon-borne and laboratory spectra. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/jd094id12p14945] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
|
41
|
Murcray DG, Goldman A, Csoeke-Poeckh A, Murcray FH, Williams WJ, Stocker RN. Nitric acid distribution in the stratosphere. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/jc078i030p07033] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
42
|
Kellosalo JAT, Kajander T, Kogan K, Pokharel K, Goldman A. The structure of a sodium pumping pyrophosphatase: clues to catalytic mechanism. Acta Crystallogr A 2012. [DOI: 10.1107/s0108767312099424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
Kajander T, Lehtinen M, Hyvärinen S, Bhattacharjee A, Meri T, Kolodziejczyk R, Meri S, Jokiranta S, Goldman A. Factor H ligand complexes – structural studies on complement regulation and disease. Acta Crystallogr A 2012. [DOI: 10.1107/s0108767312099357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Bhattacharjee A, Meri T, Kajander T, Lehtinen M, Hyvarinen S, Kolodziejczyk R, Meri S, Goldman A, Jokiranta T. The structure of factor H domains 19–20 in complex with C3d explains regulation of alternative pathway amplification on self and pathogen surfaces. Mol Immunol 2011. [DOI: 10.1016/j.molimm.2011.06.244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Corigliano MG, Maglioco A, Laguía Becher M, Goldman A, Martín V, Angel SO, Clemente M. Plant Hsp90 proteins interact with B-cells and stimulate their proliferation. PLoS One 2011; 6:e21231. [PMID: 21701588 PMCID: PMC3118808 DOI: 10.1371/journal.pone.0021231] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2010] [Accepted: 05/24/2011] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND The molecular chaperone heat shock protein 90 (Hsp90) plays an important role in folding stabilization and activation of client proteins. Besides, Hsp90 of mammals and mammalian pathogens displays immunostimulatory properties. Here, we investigated the role of plant-derived Hsp90s as B-cell mitogens by measuring their proliferative responses in vitro. METHODOLOGY Plant cytosolic Hsp90 isoforms from Arabidopsis thaliana (AtHsp81.2) and Nicotiana benthamiana (NbHsp90.3) were expressed in E. coli. Over-expression of recombinant plant Hsp90s (rpHsp90s) was confirmed by SDS-PAGE and western blot using and anti-AtHsp81.2 polyclonal anti-body. Both recombinant proteins were purified by Ni-NTA affinity chromatography and their identity confirmed by MALDI-TOF-TOF. Recombinant AtHsp81.2 and NbHsp90.3 proteins induced prominent proliferative responses in spleen cells form BALB/c mice. Polymyxin-B, a potent inhibitor of lipopolysaccharide (LPS), did not eliminate the rpHsp90-induced proliferation. In addition, in vitro incubation of spleen cells with rpHsp90 led to the expansion of CD19-bearing populations, suggesting a direct effect of these proteins on B lymphocytes. This effect was confirmed by immunofluorescence analysis, where a direct binding of rpHsp90 to B- but not to T-cells was observed in cells from BALB/c and C3H/HeN mice. Finally, we examined the involvement of Toll Like Receptor 4 (TLR4) molecules in the rpHsp90s induction of B-cell proliferation. Spleen cells from C3H/HeJ mice, which carry a point mutation in the cytoplasmic region of TLR4, responded poorly to prAtHsp90. However, the interaction between rpHsp90 and B-cells from C3H/HeJ mice was not altered, suggesting that the mutation on TLR4 would be affecting the signal cascade but not the rpHsp90-TLR4 receptor interaction. CONCLUSIONS Our results show for the first time that spleen cell proliferation can be stimulated by a non-pathogen-derived Hsp90. Furthermore, our data provide a new example of a non-pathogen-derived ligand for TLRs.
Collapse
Affiliation(s)
- Mariana G. Corigliano
- Laboratorio de Biotecnología Vegetal, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina
| | - Andrea Maglioco
- Instituto de Leucemia Experimental (ILEX)-CONICET, Academia Nacional de Medicina, Buenos Aires, Argentina
| | - Melina Laguía Becher
- Laboratorio de Biotecnología Vegetal, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina
| | - Alejandra Goldman
- CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Valentina Martín
- CESyMA, Escuela de Ciencia y Tecnología, UNSAM, San Martín, Argentina
| | - Sergio O. Angel
- Laboratorio de Parasitología Molecular, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina
| | - Marina Clemente
- Laboratorio de Biotecnología Vegetal, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina
| |
Collapse
|
46
|
Shepard DD, Kohrt HE, Rosenblat TL, Jurcic JG, Park JH, Goldman A, Dalal JS, Maslak PG, Jakubowski AA, Klimek V, Berman E, Nand S, Coutre SE, Tallman MS, Erba HP. Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Sánchez VR, Pitkowski MN, Fernández Cuppari AV, Rodríguez FM, Fenoy IM, Frank FM, Goldman A, Corral RS, Martin V. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection. Exp Parasitol 2011; 128:448-53. [PMID: 21554876 DOI: 10.1016/j.exppara.2011.04.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Revised: 03/30/2011] [Accepted: 04/26/2011] [Indexed: 10/18/2022]
Abstract
Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG-ODN) have been characterized as Th1-promoting immunopotentiators, an adjuvant activity desirable for vaccination against intracellular parasites like Toxoplasma gondii. In an attempt to find new antigen-adjuvant combinations that enhance the immunogenicity of antigen candidates for toxoplasma vaccines, we analyzed the extent of protection in mice immunized with ROP2 and GRA4 recombinant proteins when co-administered with CpG-ODN. Both GRA4+CpG-ODN and ROP2+CpG-ODN formulations were shown to induce a strong humoral Th1-biased response characterized by a high IgG(2a) to IgG(1) antibody ratio. Both vaccination regimens led to increased secretion of IFN-γ and IL-10, and negligible amounts of IL-4, upon specific re-stimulation of spleen cells from these groups of mice. After a non-lethal challenge with tissue cysts of a moderately virulent strain, only the brains from mice vaccinated with ROP2 or GRA4 in combination with CpG-ODN showed a significant reduction (63% and 62%, respectively) in their parasite load compared to the controls. The rate of protection obtained with GRA4+ROP2+CpG-ODN resulted equivalent (66%) to those achieved with the single antigens plus CpG-ODN. Taken together, these results indicate that CpG-ODN is an important candidate adjuvant for use in potential multicomponent anti-T. gondii vaccines for animals and humans.
Collapse
Affiliation(s)
- Vanesa R Sánchez
- Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, Escuela de Ciencia y Tecnología, Universidad Nacional de San Martín, Av. Gral. Paz 5445, San Martín, 1650 Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bentur A, Goldman A, Cohen MD. The Contribution of the Transition Zone to the Strength of High Quality Silica Fume Concretes. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-114-97] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTThe strength of high strength silica fume concretes is usually attributed to the reduction in w/c ratio and the refinement of the pore structure. A study of concretes and pastes, with and without silica fume, suggests that the contribution of the silica fume to strength is also the result of the densification of the transition zone. It is argued here that this influence is as important as the one due to the reduction in w/c ratio. It is suggested that the densification of the transition zone is the result of the effect of the silica fume on the nature of the fresh concrete.
Collapse
|
49
|
Xavier F, Goldwyn E, Hayes W, Carrer A, Elkhechen R, Berdichevsky M, Goldman A, Urban W, Saha S. A Comparison of the Compressive Strength of Various Distal Locking Screw Options in the Treatment of Tibia Fractures with Intramedullary Nails. J Long Term Eff Med Implants 2011; 21:185-92. [DOI: 10.1615/jlongtermeffmedimplants.v21.i3.10] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
50
|
Laguía-Becher M, Martín V, Kraemer M, Corigliano M, Yacono ML, Goldman A, Clemente M. Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. BMC Biotechnol 2010; 10:52. [PMID: 20633272 PMCID: PMC2920232 DOI: 10.1186/1472-6750-10-52] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2009] [Accepted: 07/15/2010] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Codon optimization and subcellular targeting were studied with the aim to increase the expression levels of the SAG178-322 antigen of Toxoplasma gondii in tobacco leaves. The expression of the tobacco-optimized and native versions of the SAG1 gene was explored by transient expression from the Agrobacterium tumefaciens binary expression vector, which allows targeting the recombinant protein to the endoplasmic reticulum (ER) and the apoplast. Finally, mice were subcutaneously and orally immunized with leaf extracts-SAG1 and the strategy of prime boost with rSAG1 expressed in Escherichia coli was used to optimize the oral immunization with leaf extracts-SAG1. RESULTS Leaves agroinfiltrated with an unmodified SAG1 gene accumulated 5- to 10-fold more than leaves agroinfiltrated with a codon-optimized SAG1 gene. ER localization allowed the accumulation of higher levels of native SAG1. However, no significant differences were observed between the mRNA accumulations of the different versions of SAG1. Subcutaneous immunization with leaf extracts-SAG1 (SAG1) protected mice against an oral challenge with a non-lethal cyst dose, and this effect could be associated with the secretion of significant levels of IFN-gamma. The protection was increased when mice were ID boosted with rSAG1 (SAG1+boost). This group elicited a significant Th1 humoral and cellular immune response characterized by high levels of IFN-gamma. In an oral immunization assay, the SAG1+boost group showed a significantly lower brain cyst burden compared to the rest of the groups. CONCLUSION Transient agroinfiltration was useful for the expression of all of the recombinant proteins tested. Our results support the usefulness of endoplasmic reticulum signal peptides in enhancing the production of recombinant proteins meant for use as vaccines. The results showed that this plant-produced protein has potential for use as vaccine and provides a potential means for protecting humans and animals against toxoplasmosis.
Collapse
Affiliation(s)
| | - Valentina Martín
- Escuela de Ciencia y Tecnología, UNSAM, Av. Gral. Paz 5445, San Martin, Argentina
| | - Mauricio Kraemer
- IIB-INTECH, Camino de Circunvalación km 6, Provincia de Buenos Aires, Argentina
| | - Mariana Corigliano
- IIB-INTECH, Camino de Circunvalación km 6, Provincia de Buenos Aires, Argentina
| | - María L Yacono
- IIB-INTECH, Camino de Circunvalación km 6, Provincia de Buenos Aires, Argentina
| | - Alejandra Goldman
- Escuela de Ciencia y Tecnología, UNSAM, Av. Gral. Paz 5445, San Martin, Argentina
| | - Marina Clemente
- IIB-INTECH, Camino de Circunvalación km 6, Provincia de Buenos Aires, Argentina
| |
Collapse
|